Longeveron Inc. (NASDAQ:LGVN - Get Free Report) CEO Mohamed Wa'el Ahmed Hashad bought 10,638 shares of the firm's stock in a transaction on Thursday, April 11th. The stock was purchased at an average price of $2.35 per share, for a total transaction of $24,999.30. Following the completion of the acquisition, the chief executive officer now directly owns 19,616 shares in the company, valued at $46,097.60. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website.
Longeveron Price Performance
LGVN opened at $1.69 on Friday. The business's 50 day moving average price is $4.32 and its 200 day moving average price is $12.41. The company has a current ratio of 1.50, a quick ratio of 1.50 and a debt-to-equity ratio of 0.21. Longeveron Inc. has a one year low of $1.62 and a one year high of $44.00.
Longeveron (NASDAQ:LGVN - Get Free Report) last released its quarterly earnings results on Tuesday, February 27th. The company reported ($2.50) earnings per share for the quarter, missing analysts' consensus estimates of ($2.10) by ($0.40). The business had revenue of $0.06 million for the quarter, compared to analysts' expectations of $0.21 million. Longeveron had a negative return on equity of 209.14% and a negative net margin of 3,020.17%. On average, research analysts forecast that Longeveron Inc. will post -8.5 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Longeveron
Biden out June 13; Kamala won’t replace him?
From Paradigm Press | Ad
On November 16, 2023…
Joe Biden accidentally revealed the name of the candidate…
Who will replace him in the 2024 presidential election.
See who it is HERE.
Institutional investors have recently made changes to their positions in the stock. Citadel Advisors LLC acquired a new position in shares of Longeveron in the 4th quarter worth approximately $44,000. Northern Trust Corp raised its position in Longeveron by 368.4% in the fourth quarter. Northern Trust Corp now owns 49,753 shares of the company's stock valued at $68,000 after purchasing an additional 39,130 shares during the period. Armistice Capital LLC acquired a new position in Longeveron during the fourth quarter worth $2,497,000. Boothbay Fund Management LLC purchased a new position in shares of Longeveron during the second quarter worth $254,000. Finally, Geode Capital Management LLC grew its stake in shares of Longeveron by 78.6% in the second quarter. Geode Capital Management LLC now owns 66,392 shares of the company's stock valued at $224,000 after buying an additional 29,212 shares in the last quarter. 10.01% of the stock is currently owned by institutional investors and hedge funds.
Longeveron Company Profile
(
Get Free Report)
Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young, healthy adult donors.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
